Join us Thursday 4/24 at 2pm Central Time, as we focus on the valuation range for Ford (F). Register here. HIDE

Dendreon (DNDN)

Add to Watchlists
Create an Alert
2.67 -0.01  -0.37% NASDAQ Apr 23, 3:59PM BATS Real time Currency in USD
View Full Chart
DNDN Price Chart
View All Events

DNDN Events

Date Type Description
Mar 03 Misc Dendreon Corp Q4 2013 Earning Conference Call
Mar 03 Earnings Dendreon Corp Q4 2013 Earning Result. Estimate: -0.37.
Nov 12 Misc Q3 2013 Dendreon Earnings Conference Call
Nov 12 Earnings Dendreon Announces Third Quarter 2013 Results. Estimate: -0.42.
Aug 08 Misc Q2 2013 Dendreon Earnings Conference Call
Aug 08 Earnings Dendreon to Host Conference Call on August 8 to Announce Second Quarter Financial Results. Estimate: -0.43.
May 09 Misc Q1 2013 Dendreon Earnings Conference Call
May 09 Earnings Q1 2013 Dendreon Earnings Results. Estimate: -0.46.
View All Performance Charts

DNDN Total Returns Comparison

This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Dendreon is down 41.89% over the last year vs S&P 500 Total Return up 22.59%, Actelion up 71.93%, and Regeneron Pharmaceuticals up 41.75%.

Get Quote for

Portfolio Strategies Featuring DNDN

Did Dendreon make it into our Portfolio Strategies?
Start your YCharts membership now to find out.

DNDN Profile

  • Sector: Healthcare
  • Industry: Biotechnology
  • Headquarters Country: United States
  • Headquarters State/Province: Washington
  • Incorporation Country: United States
  • Incorporation State/Province: Delaware
  • Est. Current Fiscal Quarter End: June 30, 2014
  • Est. Current Fiscal Year End: December 31, 2014
  • Last Fiscal Quarter End: N/A
  • Last Fiscal Year End: N/A
  • NAICS: Pharmaceutical Preparation Manufacturing
  • NAICS Code: 325412
  • NAICS Industry: Pharmaceutical and Medicine Manufacturing
  • NAICS Industry Code: 3254
  • NAICS Sector: Manufacturing
  • NAICS Sector Code: 32

Dendreon Corporation is a biotechnology company focused on targeting cancer and transforming lives through the discovery, development, commercialization, and manufacturing of novel therapeutics that may significantly improve cancer treatment options for patients. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response. Dendreon is headquartered in Seattle and has manufacturing facilities in New Jersey, Georgia, and California. The company was founded in 1992.

Recent Quotes

Symbol Price Chg Chg % Market Cap
DNDN 2.67 -0.01 -0.37% 424.46M
Create Watchlist from Quotes

Already registered? Click here to sign in.

Access watchlists and custom data alerts.
Start your free account.

Get Started Now

Upgrade to {{}}. Start Your YCharts Membership. Start your {{}} Membership


{{ ? "Upgrade Now" : "Get Started Now"}}

Already a YCharts Member? Already a {{}} Member? Sign in here.